【财华社讯】励晶太平洋(00575.HK)公布，公司全资附属公司Deep Longevity, Inc及其附属公司委任 Dylan Kay为美国首席商务官及Luke Shaffer为美国销售副总裁，二人均将于2026年1月1日正式履新。此 次委聘标志着Deep Longevity积极进驻全球最大的健康市场-美国，且已定于2026年第一季度启动商业化 营运。 本文源自：财华网 ...

智通财经APP讯，励晶太平洋(00575)发布公告，全球可解释人工智能驱动老化时钟与长寿科学的领导者 Deep Longevity, Inc及其附属公司(统称"Deep Longevity")委任Dylan Kay为美利坚合众国(美国)首席商务 官及Luke Shaffer为美国销售副总裁，二人均将于2026年1月1日正式履新。 •诊断实验室及长寿诊所 •高端消费者健康平台 Deep Longevity经临床验证的老化时钟 - 包括BloodAge、EpigeneticAge、 MindAge、BiometricAge、及 即将推出的FaceAge - 能够从分子、生理、认知及心理老化层面，提供多模态、可执行的洞察。Deep Longevity的软件即服务(SaaS)© 解决方案使雇主及保险公司能够从被动的疾病护理转型为提供经证实可 延长健康寿命并降低长期成本的可量化的个人化长寿计划。 Deepankar Nayak(Deep Longevity行政总裁)表示，"目前，美国每年4.5万亿美元的医疗支出中，90%都源 于慢性疾病。Dylan与Luke是久经考验的实干型人才，彼等多次将新兴科学转化为企业级影响力。 ...

格隆汇12月10日丨励晶太平洋(00575.HK)发布公告，全球可解释人工智能驱动老化时钟与长寿科学的领 导者Deep Longevity, Inc及其附属公司(统称" Deep Longevity ")委任Dylan Kay为美国首席商务官及Luke Shaffer为美国销售副总裁，二人均将于2026年1月1日正式履新。此次委聘标志着Deep Longevity积极进 驻全球最大的健康市场－美国，且已定于2026年第一季度启动商业化营运。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：���） 自願性更新營運情況 Deep Longevity於美國的業務擴展及 啟動二零二六年前委任主要高管 本公佈乃勵晶太平洋集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）按自願基準而作出，以知會本公司股東及潛在投資者下列 有關其營運的最新情況。 本 公 司 今 日 宣 佈，全 球 可 解 釋 人 工 智 能 驅 動 老 化 時 鐘 與 長 壽 科 學 的 領 導 者 Deep Longevity, Inc及其附屬公司（統稱「Deep Longevity」）委任Dylan Kay為 美利堅合眾國（「美國」）首席商務官及Luke Shaffer為美國銷售副總裁，二人均將於 二零二六年一月一日正式履新。 此次委聘標誌著Deep Longevity積極進駐全球最大的健康市場 － 美國，且已定於 二零二六年第一季度啟動商業 ...

Core Viewpoint - The stock price of Lattice Technology (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting the rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lattice Technology's stock has shown significant growth, with a current increase of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity in the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - Lijing Pacific (00575.HK) experienced a significant stock price increase, closing up over 12% and reaching a rise of 31.25% at 1.05 HKD per share, with a trading volume of 648,600 HKD [2] Summary by Category - **Stock Performance** - The stock price of Lijing Pacific rose by over 12% yesterday and is currently up 31.25% [2] - The closing price reached 1.05 HKD per share [2] - The total trading volume was 648,600 HKD [2]

Core Viewpoint - The stock of Lijing Pacific (00575) experienced a significant increase, rising over 12% yesterday and more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD. This surge is attributed to the announcement of its subsidiary, Deep Longevity, expanding into the U.S. market in Q1 of next year, targeting a rapidly growing health market valued at over 6.8 trillion USD [1]. Company Summary - Lijing Pacific's stock price has shown a remarkable increase, with a current rise of 31.25% [1]. - The company’s subsidiary, Deep Longevity, is recognized as a leader in AI-driven aging clocks and longevity science [1]. - The expansion plan into the U.S. market is set to position Deep Longevity within the largest and fastest-growing segment of the health market [1]. Industry Summary - The health market, which Deep Longevity aims to enter, is currently valued at over 6.8 trillion USD, indicating substantial growth potential [1].

Core Viewpoint - The stock price of Lattice Technology Pacific (00575) surged over 12% yesterday and increased by more than 35% today, currently trading at 1.05 HKD with a transaction volume of 648,600 HKD [1] Company Summary - Lattice Technology Pacific announced that its wholly-owned subsidiary, Deep Longevity, a leader in AI-driven aging clocks and longevity science, will initiate an expansion plan into the U.S. market in the first quarter of next year [1] - This expansion will position Deep Longevity in the core of the largest and fastest-growing health market globally, which is currently valued at over 6.8 trillion USD [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00575 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 143,000,000,000 | | USD | | 0.001 USD | | 143,000,000 | | 增加 / 減少 (-) | | | | 0 | | USD | | | | 本月底結存 | | 143,000,000,000 | | USD | | 0.001 USD | | 143,000,000 | | 2. 股份分類 | 其他分類 (請註明) | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | ...

美国对基于实证的长寿解决方案展现出无可比拟的规模与需求。Deep Longevity 经临床验证的深度老化 时钟 - 包括BloodAge、MindAge、BiometricAge、 EpigeneticAge及即将推出的FaceAge - 提供远超过时 序年龄的精准且多维度的生物年龄评估。该等工具赋予消费者、医生、雇主及保险公司可执行及个人化 的洞察力，以延长健康寿命并延缓老化。 智通财经APP讯，励晶太平洋(00575)发布公告，全球可解释人工智能驱动老化时钟与长寿科学的领导者 Deep Longevity, Inc及其附属公司(统称Deep Longevity)将于2026年第一季度启动进军美利坚合众国(美国) 的扩张计划。此举将使Deep Longevity挤身于全球规模最大且增长最迅速的健康市场核心，该市场当前 估值逾6.8万亿美元。 Deep Longevity的技术已获得数十篇同行评审论文及多项授权专利的支持。其多模态老化时钟整合血液 生物标志物、表观遗传学、心理学、生物学，及将整合的面部成像以提供当今最全面的生物老化画像。 为推动快速普及，Deep Longevity正组建美国本土销售团队，首 ...